June 3, 2023 03:06 PM EDTUpdated 05:28 PM

AstraZeneca trial shows modest benefit in ovarian cancer, but doctors say it's hard to apply findings: #ASCO23

Lei Lei Wu

News Reporter

CHICAGO — Adding AstraZeneca’s Imfinzi and Lynparza to the treatment regimen for patients with advanced ovarian cancer and no BRCA mutation extended progression-free survival (PFS) by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca trial shows modest benefit in ovarian cancer, but doctors say it's hard to apply findings: #ASCO23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

As­traZeneca tri­al shows mod­est ben­e­fit in ovar­i­an can­cer, but doc­tors say it's hard to ap­ply find­ings: #AS­CO23

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca trial shows modest benefit in ovarian cancer, but doctors say it's hard to apply findings: #ASCO23